Arbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 1,104,337 shares were traded during trading, a decline of 2% from the previous session's volume of 1,126,825 shares.The stock last traded at $2.93 and had previously closed at $2.92.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on ABUS shares. Chardan Capital reiterated a "buy" rating and set a $4.00 price target on shares of Arbutus Biopharma in a report on Friday, March 1st. JMP Securities reiterated a "market outperform" rating and set a $4.00 price target on shares of Arbutus Biopharma in a report on Thursday. Finally, HC Wainwright decreased their target price on Arbutus Biopharma from $6.00 to $5.00 and set a "buy" rating on the stock in a research note on Friday, March 1st.
Check Out Our Latest Stock Analysis on Arbutus Biopharma
Arbutus Biopharma Stock Performance
The company has a 50 day moving average of $2.67 and a 200-day moving average of $2.27. The stock has a market cap of $538.47 million, a price-to-earnings ratio of -6.82 and a beta of 2.03.
Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last posted its earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). The firm had revenue of $2.15 million for the quarter, compared to analyst estimates of $4.74 million. Arbutus Biopharma had a negative return on equity of 57.82% and a negative net margin of 401.57%. During the same quarter in the prior year, the company earned ($0.14) EPS. On average, research analysts anticipate that Arbutus Biopharma Co. will post -0.39 EPS for the current year.
Institutional Investors Weigh In On Arbutus Biopharma
Hedge funds have recently bought and sold shares of the stock. Pathstone Holdings LLC acquired a new stake in shares of Arbutus Biopharma during the 4th quarter worth about $25,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Arbutus Biopharma in the second quarter valued at approximately $27,000. Verition Fund Management LLC purchased a new stake in shares of Arbutus Biopharma in the second quarter valued at approximately $28,000. Principal Financial Group Inc. purchased a new stake in shares of Arbutus Biopharma in the second quarter valued at approximately $32,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Arbutus Biopharma in the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 43.79% of the company's stock.
About Arbutus Biopharma
(
Get Free Report)
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Read More
Before you consider Arbutus Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arbutus Biopharma wasn't on the list.
While Arbutus Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
